Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in ALS with Depressed Mood
NCT06656702Phase 1Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Apr 2025
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in major depressive disorder (MDD), sponsored by Johns Hopkins University. Primary endpoint: Feasibility of psilocybin treatment at 6 months. Started Apr 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06656702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06656702.